FcRn Inhibitor Clinical Trials: Shaping the Future of Autoimmune Therapy
FcRn Inhibitor Clinical Trials: Shaping the Future of Autoimmune Therapy FcRn Inhibitor: Transforming the Landscape of Autoimmune Disease Treatment The FcRn Inhibitor class of therapies has emerged as a breakthrough in the management of autoimmune diseases driven by pathogenic immunoglobulin G (IgG) antibodies. By targeting the neonatal Fc receptor (FcRn), these inhibitors prevent the recycling of IgG, leading to their accelerated degradation and reduced levels in circulation. This mechanism offers a promising treatment pathway for conditions such as myasthenia gravis, pemphigus vulgaris, immune thrombocytopenia, and other antibody-mediated disorders. The Science Behind FcRn Inhibitors The neonatal Fc receptor plays a crucial role in protecting IgG antibodies from degradation. While this function is essential for immune defense, it becomes problematic in autoimmune diseases where IgG antibodies mistakenly attack healthy tissues. An FcRn Inhibitor blocks this receptor, reducing ...